Guardant Health financials
$177.73+0.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M | $286.7M | $214.4M | $90.6M |
| Gross profit | $633.0M | $449.2M | $336.9M | $293.2M | $250.7M | $194.2M | $143.7M | $47.4M |
| Gross margin | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% | 67.7% | 67.0% | 52.3% |
| Operating income | -$437.2M | -$443.6M | -$564.7M | -$544.4M | -$411.0M | -$254.9M | -$82.4M | -$92.9M |
| Net income | -$416.3M | -$436.4M | -$479.4M | -$654.6M | -$405.7M | -$253.8M | -$75.7M | -$85.1M |
| Net margin | −42.4% | −59.0% | −85.0% | −145.6% | −108.6% | −88.5% | −35.3% | −93.8% |
| Diluted EPS | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | $-2.80 |
| EBITDA | -$397.5M | -$401.2M | -$521.8M | -$508.4M | -$388.7M | -$238.9M | -$71.0M | -$85.8M |
| Operating cash flow | -$184.8M | -$239.9M | -$325.0M | -$313.8M | -$209.0M | -$103.9M | -$47.1M | -$72.2M |
| Free cash flow | -$233.1M | -$274.9M | -$345.5M | -$391.2M | -$284.1M | -$140.1M | -$65.9M | -$92.4M |
| Diluted shares | 125.4M | 122.7M | 112.0M | 102.2M | 101.3M | 97.5M | 90.6M | 30.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $378.2M | $525.5M | $1.13B | $141.6M | $492.2M | $833.0M |
| Short-term investments | $823.4M | $314.4M | $35.1M | $869.6M | $440.5M | $961.9M |
| Total debt | $1.50B | $1.14B | $1.14B | $1.14B | $1.13B | $806.3M |
| Total assets | $2.01B | $1.49B | $1.79B | $1.61B | $2.20B | $2.27B |
| Total liabilities | $2.11B | $1.63B | $1.63B | $1.55B | $1.56B | $916.2M |
| Shareholders' equity | -$99.3M | -$139.6M | $158.7M | $60.2M | $645.0M | $1.30B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology